Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.

European journal of clinical pharmacology - 1 Sept 2013

Niioka Takenori, Kagaya Hideaki, Miura Masatomo, Numakura Kazuyuki, Saito Mitsuru, Inoue Takamitsu, Habuchi Tomonori, Satoh Shigeru

Abstract excerpt

PURPOSE: The pharmacokinetics of orally administered immediate-release, twice-daily (BID) and modified-release, once-daily (QD) formulations of tacrolimus have high interindividual variability. We investigated factors affecting interindividual variability of tacrolimus bioavailability in renal transplant patients. METHODS: Ninety-seven Japanese renal transplant patients (47 patients on tacrolimus BID and 50...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biological Availability

Share to Cytochrome P-450 CYP3A

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Polymorphism, Single Nucleotide

Share to Tacrolimus

Source

Identifiers

PMID: 23733010
DOI: 10.1007/s00228-013-1514-8

Genes

BID

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients.PMID 23733010Read ↗

A systematic review of the effect of CYP3A5 genotype on the apparent oral clearance of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatmentSemantic proximity Read ↗

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.Semantic proximity Read ↗

Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.Semantic proximity Read ↗

Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.Semantic proximity Read ↗

Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients.Semantic proximity Read ↗

Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients.Semantic proximity Read ↗

Effects of CYP3A5, ABCB1 and POR*28 polymorphisms on pharmacokinetics of tacrolimus in the early period after renal transplantation.Semantic proximity Read ↗

Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.Semantic proximity Read ↗

Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.